PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery Technology for Psychedelics and Antivirals

/

PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company and TSRL, Inc. (“TSRL”), a company focused on developing microneedle patches for the delivery of antivirals for the treatment of influenza, are pleased to announce that PharmaTher and TSRL (collectively the “Companies”) entered into a Co-Development Agreement to jointly develop a microneedle array patch with the aim to control the manufacturing and supply of microneedle patches for the Companies respective clinical and commercial drug programs.

Read More

TSRL, Inc. Awarded Two NIH Grants to Develop Therapeutics for Multi-Drug Resistant Infections

/
TSRL, Inc. Awarded Two NIH Grants to Develop Therapeutics for Multi-Drug Resistant Infections

ANN ARBOR, MICHIGAN, August 10th, 2017—TSRL, Inc., a privately-held preclinical accelerator, announced today that the company was awarded a Phase I Small Business Technology Transfer (STTR) grant and a Direct-to-Phase II Small Business Innovation Research (SBIR) grant from the National Institute of Allergy & Infectious Diseases (NIAID) of the National Institute of Health (NIH).

Read More

TSRL, Inc. Awarded NIH Grant to Develop Microneedle Patch for Treatment of Influenza

/
TSRL, Inc. Awarded NIH Grant to Develop Microneedle Patch for Treatment of Influenza

ANN ARBOR, MICHIGAN, February 17, 2017—TSRL, Inc., announced today that the company was awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Allergy & Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). TSRL will receive approximately $600,000 over the next two years for the development of a transdermal delivery system of zanamivir (GSK, Relenza®), an inhalation drug product used in the treatment of influenza A & B.

Read More